Brief: Mayne Pharma Posts QTRLY Underlying EBITDA Of -A$1.4 Million
29/04/2026 02:23
April 29 (Reuters) - Mayne Pharma Group Ltd MYX.AX: QTRLY UNDERLYING EBITDA OF -A$1.4 MILLION NO MATERIAL EARNINGS IMPACT FROM US TARIFF PROCLAMATION ON 7 APRIL QTRLY REVENUE A$85.2 MILLION CONTINUES TO EXAMINE CAPITAL ALLOCATION STRATEGIES, MAY INCLUDE ON-MARKET SHARE BUY-BACK Further company coverage: MYX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mayne Pharma
See all newsBrief: Mayne Pharma Group Says It Settles Us Patent Litigation Re Imvexxy With Teva USA
Deals of the day-Mergers and acquisitions
Brief: Mayne Pharma Says Supreme Court Dismisses Cosette Appeal
Deals of the day-Mergers and acquisitions
Australian court dismisses Cosette appeal to drop Mayne Pharma takeover (updated)